Top Markets
Coin of the day
Abnova (Taiwan) Corporation Abnova (Taiwan) Corporation

Abnova (Taiwan) Corporation

4133
株式のランク #26497
Abnova (Taiwan) Corporation specializes in the development and distribution of... Abnova (Taiwan) Corporation specializes in the development and distribution of a comprehensive range of recombinant proteins and antibodies. The company's extensive product portfolio caters to diverse research and diagnostic applications, featuring specialized reagents for SARS-CoV/CoV-2, nucleic acids (both DNA and RNA), and various proteins and peptides. Their offerings further include items like DNAxPab, laboratory beads, dyes, cellular lysates, microscopic slides, antibody pairs and associated kits, as well as antibody and tissue arrays. Additionally, they provide in situ hybridization products, advanced laboratory systems and automation, GMP-grade and analyte-specific reagents, and solutions for in vitro diagnostics. Beyond these product lines, Abnova supplies a broad spectrum of antibody types, such as MaxPab, monoclonal, polyclonal, recombinant, conjugate, secondary/tag, IHC/pathology, and those specifically targeting circulating rare cells. The company also delivers integrated solutions and services, encompassing gene synthesis and cytogenetic analysis, peptide services, protein expression and conjugations, custom antibody generation, and assay development. Abnova (Taiwan) Corporation operates from its headquarters in Taipei, Taiwan.
株価
$0.66300973
時価総額
$40.15M
変化(1日)
1.46%
変化(1年)
-20.61%
TW
取引 Abnova (Taiwan) Corporation (4133)

カテゴリー

Abnova (Taiwan) Corporation(4133)の収益
Aug 2026 時点の収益 TTM: 0
Abnova (Taiwan) Corporation の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Abnova (Taiwan) Corporation の収益履歴(2026 ~ 2026)
各年末の収益
収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差
$12.62B -
US
$6.02B -
NL
$15.70B -
AU
- -
CH
$2.23B -
US